Alzheimer disease (AD) is the most common form of dementia. AD is characterized by amyloid plaques and neurofibrillary tangles in the brain, with associated loss of synapses and neurons, … [Read more...] about TAU Me One More Time
Novo Nordisk (NYSE: NVO) is a global healthcare company engaged in diabetes care, obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other … [Read more...] about Is Novo Nordisk Ready For Increased Biosimilar Competition?
Introduction Trevena Inc. (Nasdaq: TRVN) spiked 119% from the $.5 range to $1.19 on January 28th. The catalyst being positive regulatory updates from the FDA Type A meeting minutes. In a … [Read more...] about 2019 Should Be A Good Year For TRVN, But What’s Next?
Leave a comment and click here to sub for MS Equity Analysis and Swing Moves. Introduction You may have recently seen hype about Corbus Pharmaceuticals (Nasdaq: CRBP), … [Read more...] about CRBP – Is Corbus Pharmaceuticals a good buy?
Introduction Bristol-Myers Squibb (NYSE: BMY) is a profitable global bio-pharmaceutical company targeting an array of serious diseases and unmet medical needs. Earlier this month BMY announced … [Read more...] about Bristol-Myers Squibb Positioned For Deep Penetration In the Multiple Myeloma Market
Leave a comment and click here to sub for MS article alerts and our newsletter! What's new? VSTM added to NASDAQ Biotech Index Hedge funds increase positions Analysts maintain $10+ PT … [Read more...] about Where Is VSTM Headed?
Leave a comment and click here to sub for MS article alerts and our newsletter! Overview January 14th, the FDA approved cabozantinib (CABOMETYX) for the treatment of hepatocellular carcinoma (HCC) in … [Read more...] about FDA Approves Cabozantinib; But it’s Not Alone
Introduction Adma Biologics (Nasdaq: ADMA $2.23) is a commercial bio-pharmaceutical company vertically integrated to develop, market, manufacture, and sell specialty plasma-derived products called … [Read more...] about ADMA Tanks After Receiving A CRL For BIVIGAM’s PAS Submission -Should You Buy?
Note to followers: We apologize for not having the scheduled article on Bristol-Myers Squibb's penetration into the Multiple Myeloma Market ready for publication today. Sultan became ill and couldn't … [Read more...] about An Overview of STXS 3rd Quarter Financial Results And Insider Selling
Leave a comment and click here to sub for MS article alerts and our newsletter Introduction Investors and watchers of VSTM were elated to receive positive news from the FDA in late September … [Read more...] about VSTM- A Reduced Risk Oncology Company